Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
| Revenue (TTM) | $181.68M |
| Gross Profit (TTM) | $74.77M |
| EBITDA | $38.91M |
| Operating Margin | 15.40% |
| Return on Equity | 7.97% |
| Return on Assets | 4.19% |
| Revenue/Share (TTM) | $3.12 |
| Book Value | $4.50 |
| Price-to-Book | 1.54 |
| Price-to-Sales (TTM) | 2.24 |
| EV/Revenue | 1.85 |
| EV/EBITDA | 8.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.80% |
| Shares Outstanding | $57.69M |
| Float | $31.45M |
| % Insiders | 7.20% |
| % Institutions | 48.51% |
Volatility is currently expanding
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization
REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company's new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.
Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues ; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company's Products Continues to Increase, Supporting the Company's Expectation for a Significantly Stronger Remainder of 2026 Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Annual Double-Digit Organic Profitable Growth Q1-2026 Results Impacted by Temporary Shipment Delay of a Single Order, Subsequently Delivered during April Company Continues to Evaluate Near-Term Business Development and M&A Transactions to Further Enhance Long-Term Profitable Growth Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Get a deeper insight into the potential performance of Kamada (KMDA) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma's collection center in San Antonio, TX. The approval was obtained following an on-site inspection made by the FDA during February 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KMDA and any ticker you trade — then tracks every position and per-strategy win rate.
